Cipla Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2fqtz8f73wch668vwgwpbn8w.pdf

Key Takeaways


U.S. Business & the $1 Billion Exit

Achin Gupta: "We have a very good chance of being the first and potentially being the only one."

India Business

Achin Gupta: "Our bet has been fairly clear. We wanted to work with innovator product, which has dual mode of action to receptors. So, we've invested behind tirzepatide."

Margin Walk & the Transit Phase

Ashish Adukia: "This is more a transit phase for Cipla... what you saw last quarter and this quarter is not our steady state is the point that we're trying to..."

Rest of World & Diversification


Pipeline, Regulatory & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
U.S. revenue exit rate$1 billion, predicated on Ventolin scale-up, three respiratory launches, and one peptide launchQ4 FY27 exit
EBITDA margin18.5% to 20% for FY27, dependent on new launch timingFY27
Ventolin full ramp-upManufacturing scale-up and approvals to reach full volumeEnd of FY27
Gross margin improvementExpected as winter recipe mix lifts product mixQ3 FY27
Indore facility reinspectionFDA reinspection expected"Anytime soon"
InvaGen Advair approvalApproval expected following February inspection with two observations"Any time"

Key Metrics

MetricQ1 FY27
Revenue₹7,119 cr, +2% YoY reported; +4% YoY adjusted for accounting change
One India revenue growth12% YoY, highest ever quarterly revenue
Branded prescription growth (IQVIA)15.4%, driven by chronic portfolio
EBITDA margin (ex-other income)16.7%, impacted by product mix, war-related costs, inventory charges, and phasing of incentives
Gross margin after material cost62.5%, incorporating product mix, war costs, inventory charges, and incentive phasing
Profit after tax₹789 cr, 11% of sales; ETR at 27%
R&D spend₹486 cr, 6.8% of revenue
North America revenue$162 million, Cipla holds #1 position in U.S. Albuterol MDI market at 21% share
U.S. Albuterol MDI market share21%, per IQVIA data for week ending June 2026
South Africa private market secondary growth6.5%, outperforming market growth of 5.7% per IQVIA MAT
EMEU growth (USD terms)5% YoY, fueled by DTM and B2B segments
Chronic mix60.4% of domestic business, up YoY
Net cash₹9,494 cr, after dividend payment of ₹1,050 cr; debt including lease liabilities at ₹600 cr
Yurpeak (tirzepatide) revenue~₹80 cr in Q1, second largest brand in category per IQVIA
War-related cost impact~1% to 2% of revenue, per current estimate
EBITDA margin guidance for FY2718.5% to 20%, unchanged, predicated on new launches and margin improvement